{
    "title": "Amicus' muscle disorder therapy gets US FDA nod but restricted label drags shares",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12571651/US-FDA-approves-Amicus-Therapeutics-muscle-disorder-treatment.html",
    "date": "2023-09-28",
    "keywords": [
        "therapy",
        "disease",
        "use",
        "treatment",
        "drug",
        "roy",
        "pompe",
        "health",
        "regulator",
        "replacement",
        "label",
        "analyst",
        "market",
        "sanofi",
        "standard",
        "care",
        "glycogen",
        "condition",
        "muscle",
        "disorder",
        "drugmaker",
        "thursday",
        "yearslong",
        "food",
        "kg",
        "improvement",
        "europe",
        "latestage",
        "trial",
        "approval",
        "entry",
        "battle",
        "share",
        "gil",
        "decision",
        "october",
        "time",
        "review",
        "travel",
        "amicus",
        "price",
        "patient",
        "labmade",
        "protein",
        "alphaglucosidase",
        "migalastat",
        "brand",
        "name",
        "opfolda",
        "body",
        "sugar",
        "buildup",
        "impairment",
        "heart",
        "failure",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli",
        "sriraj",
        "kalluvila",
        "shweta",
        "agarwal"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}